INR 434.5
(7.04%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 2.6 Billion INR | -8.23% |
2022 | 2.51 Billion INR | -12.0% |
2021 | 2.76 Billion INR | -53.29% |
2020 | 6.16 Billion INR | 4.5% |
2019 | 5.89 Billion INR | 40.87% |
2018 | 4.2 Billion INR | 243.03% |
2017 | 1.25 Billion INR | 40.68% |
2016 | 1.03 Billion INR | 134.89% |
2015 | 514.62 Million INR | 385.57% |
2014 | -55.03 Million INR | -92.12% |
2013 | 970.56 Million INR | 7.5% |
2012 | 890.59 Million INR | 25.56% |
2011 | 709.32 Million INR | 1.91% |
2010 | 673.36 Million INR | 76.06% |
2009 | 395.32 Million INR | 9.75% |
2008 | 360.18 Million INR | -2.0% |
2007 | 367.53 Million INR | 95.14% |
2006 | 188.35 Million INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 511.1 Million INR | -10.4% |
2023 FY | - INR | -8.23% |
2023 Q1 | 795.8 Million INR | -23.5% |
2023 Q2 | 713.1 Million INR | -10.39% |
2023 Q3 | 527.3 Million INR | -26.06% |
2023 Q4 | 495.2 Million INR | -6.09% |
2022 FY | - INR | -12.0% |
2022 Q2 | 369.7 Million INR | -39.34% |
2022 Q3 | 493.4 Million INR | 33.46% |
2022 Q1 | 609.5 Million INR | 28.94% |
2022 Q4 | 1.04 Billion INR | 110.82% |
2021 Q1 | 1.15 Billion INR | 2.92% |
2021 Q2 | 543.1 Million INR | -53.13% |
2021 FY | - INR | -53.29% |
2021 Q3 | 680.9 Million INR | 25.37% |
2021 Q4 | 472.7 Million INR | -30.58% |
2020 Q3 | 1.65 Billion INR | -6.1% |
2020 FY | - INR | 4.5% |
2020 Q1 | 1.57 Billion INR | 15.03% |
2020 Q4 | 1.12 Billion INR | -31.79% |
2020 Q2 | 1.75 Billion INR | 11.31% |
2019 Q2 | 1.36 Billion INR | -7.86% |
2019 Q3 | 1.63 Billion INR | 19.92% |
2019 Q4 | 1.37 Billion INR | -16.01% |
2019 FY | - INR | 40.87% |
2019 Q1 | 1.47 Billion INR | -4.31% |
2018 Q4 | 1.54 Billion INR | 13.37% |
2018 Q2 | 808.9 Million INR | 86.25% |
2018 FY | - INR | 243.03% |
2018 Q1 | 434.3 Million INR | 22.55% |
2018 Q3 | 1.36 Billion INR | 68.57% |
2017 Q1 | 276.2 Million INR | 4.27% |
2017 FY | - INR | 40.68% |
2017 Q4 | 354.4 Million INR | 8.11% |
2017 Q3 | 327.8 Million INR | 9.19% |
2017 Q2 | 300.2 Million INR | 8.69% |
2016 FY | - INR | 134.89% |
2016 Q2 | 254.8 Million INR | -0.84% |
2016 Q3 | 257 Million INR | 0.86% |
2016 Q1 | 256.94 Million INR | 180.92% |
2016 Q4 | 264.9 Million INR | 3.07% |
2015 Q2 | 82.39 Million INR | 283.39% |
2015 Q4 | 91.46 Million INR | -46.51% |
2015 Q1 | 21.49 Million INR | 115.4% |
2015 Q3 | 171 Million INR | 107.53% |
2015 FY | - INR | 385.57% |
2014 Q4 | -139.54 Million INR | -36.14% |
2014 Q3 | -102.5 Million INR | -249.0% |
2014 Q1 | 248.7 Million INR | 10.23% |
2014 FY | - INR | -92.12% |
2014 Q2 | 68.79 Million INR | -72.34% |
2013 Q4 | 225.61 Million INR | -4.52% |
2013 Q2 | 251.14 Million INR | 2.7% |
2013 Q1 | 244.54 Million INR | 25.56% |
2013 Q3 | 236.28 Million INR | -5.92% |
2013 FY | - INR | 7.5% |
2012 Q4 | 194.76 Million INR | -18.62% |
2012 Q3 | 239.31 Million INR | 6.83% |
2012 Q2 | 224.01 Million INR | -3.67% |
2012 Q1 | 232.53 Million INR | 0.0% |
2012 FY | - INR | 25.56% |
2011 FY | - INR | 1.91% |
2010 FY | - INR | 76.06% |
2009 FY | - INR | 9.75% |
2008 FY | - INR | -2.0% |
2007 FY | - INR | 95.14% |
2006 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Sigachi Industries Limited | 883.39 Million INR | -195.065% |
Ind-Swift Limited | 1.06 Billion INR | -144.736% |
Bajaj HealthCare Limited | 406.23 Million INR | -541.644% |
Sakar Healthcare Limited | 393.26 Million INR | -562.805% |
Aurobindo Pharma Limited | 61.78 Billion INR | 95.781% |
Innova Captab Limited | 1.66 Billion INR | -56.242% |
Divi's Laboratories Limited | 25.43 Billion INR | 89.75% |
AstraZeneca Pharma India Limited | 2.35 Billion INR | -10.599% |
Morepen Laboratories Limited | 1.72 Billion INR | -51.024% |
Mankind Pharma Limited | 28.09 Billion INR | 90.722% |
Sequent Scientific Limited | 549.8 Million INR | -374.1% |
Wanbury Limited | 985.49 Million INR | -164.498% |
Laurus Labs Limited | 8 Billion INR | 67.442% |
Nectar Lifesciences Limited | 1.53 Billion INR | -69.746% |
Glenmark Life Sciences Limited | 6.86 Billion INR | 62.019% |
Alembic Limited | 1.11 Billion INR | -133.495% |
Hikal Limited | 2.69 Billion INR | 3.181% |
Alembic Pharmaceuticals Limited | 9.61 Billion INR | 72.895% |
Neuland Laboratories Limited | 4.74 Billion INR | 45.103% |
J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 72.077% |
Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 77.022% |
Themis Medicare Limited | 562.6 Million INR | -363.307% |
RPG Life Sciences Limited | 1.28 Billion INR | -103.402% |
Zydus Lifesciences Limited | 56.22 Billion INR | 95.364% |
Lupin Limited | 36.96 Billion INR | 92.949% |
Amrutanjan Health Care Limited | 681.59 Million INR | -282.426% |
Wockhardt Limited | 1.08 Billion INR | -141.352% |
Vaishali Pharma Limited | 31.71 Million INR | -8119.861% |
Aarti Pharmalabs Limited | 3.9 Billion INR | 33.325% |
Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -705.849% |
Jubilant Pharmova Limited | 8 Billion INR | 67.442% |
FDC Limited | 3.38 Billion INR | 23.004% |
Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 97.047% |
Kilitch Drugs (India) Limited | 287.42 Million INR | -806.88% |
Eris Lifesciences Limited | 6.98 Billion INR | 62.691% |
Venus Remedies Limited | 711.8 Million INR | -266.198% |
ZIM Laboratories Limited | 462.09 Million INR | -464.081% |
Bliss GVS Pharma Limited | 1.47 Billion INR | -76.237% |
Par Drugs and Chemicals Limited | 228.17 Million INR | -1042.374% |
Caplin Point Laboratories Limited | 6.18 Billion INR | 57.848% |
Shilpa Medicare Limited | 2.58 Billion INR | -0.719% |
Albert David Limited | 1.04 Billion INR | -149.334% |
Ajanta Pharma Limited | 12.56 Billion INR | 79.256% |
Hester Biosciences Limited | 539.47 Million INR | -383.178% |
Suven Pharmaceuticals Limited | 4.67 Billion INR | 44.27% |
Solara Active Pharma Sciences Limited | -2.82 Billion INR | 192.37% |
Gufic Biosciences Limited | 1.48 Billion INR | -76.064% |
Windlas Biotech Limited | 781.72 Million INR | -233.444% |
Procter & Gamble Health Limited | 3.07 Billion INR | 15.216% |
Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -5671.283% |
Mangalam Drugs & Organics Limited | 174.94 Million INR | -1389.945% |
Granules India Limited | 8.6 Billion INR | 69.704% |
Aarti Drugs Limited | 3.24 Billion INR | 19.763% |
Bal Pharma Limited | 345.59 Million INR | -654.242% |
Alkem Laboratories Limited | 24.19 Billion INR | 89.227% |
Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.116% |
Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -94.041% |
Medicamen Biotech Limited | 245.66 Million INR | -961.06% |
Unichem Laboratories Limited | 742.35 Million INR | -251.125% |
Bafna Pharmaceuticals Limited | 114.58 Million INR | -2174.858% |
Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -19956.941% |
Valiant Laboratories Limited | 12.73 Million INR | -20361.575% |
Orchid Pharma Limited | 1.41 Billion INR | -83.67% |
Medico Remedies Limited | 129.09 Million INR | -1919.149% |
Ind-Swift Laboratories Limited | 6.86 Billion INR | 62.012% |
Ipca Laboratories Limited | 13.29 Billion INR | 80.401% |
Brooks Laboratories Limited | 41.72 Million INR | -6146.645% |
Syncom Formulations (India) Limited | 430.27 Million INR | -505.797% |
Piramal Enterprises Limited | -3.86 Billion INR | 167.509% |
Torrent Pharmaceuticals Limited | 35 Billion INR | 92.555% |
NATCO Pharma Limited | 18.79 Billion INR | 86.131% |
Suven Life Sciences Limited | -992.78 Million INR | 362.556% |
Krebs Biochemicals & Industries Limited | -82.72 Million INR | 3250.846% |
Strides Pharma Science Limited | 3.76 Billion INR | 30.762% |
Indoco Remedies Limited | 2.64 Billion INR | 1.528% |
Alpa Laboratories Limited | 229.96 Million INR | -1033.497% |
Lasa Supergenerics Limited | -65.08 Million INR | 4105.224% |
Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 169.855% |